Evidence map›Paper›PMID 41660640›Full record

ReviewResearch (Washington, D.C.)2026

Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.

Yejiao Shi, Yuting Li, Zhinan Liu, Xiangxiang Kong, Xiaochun Hu, Xi Liu, Cuiping Zhang, Honggang Hu

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yejiao ShiInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.ORCID https://orcid.org/0000-0002-1648-0833
Yuting LiInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Zhinan LiuInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Xiangxiang KongInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Xiaochun HuShanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai 200444, China.
Xi LiuMedical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing 100143, China.
Cuiping ZhangMedical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing 100143, China.
Honggang HuInstitute of Translational Medicine, Shanghai Jiao Tong University, Shanghai 200030, China.ORCID https://orcid.org/0000-0003-0577-3021

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overuse and misuse of antibiotics have led to widespread resistance in bacteria, which makes infections difficult to treat. The insufficient prevention measures, limited treatment options, and delayed antibiotic developments call for immediate global actions to discover effective and safe treatments for bacterial infections. Over the past decades, more and more studies have found that bacterial extracellular vesicles (BEVs) secreted by bacteria with nanoscale size, lipid bilayer structure, pathogen-associated molecular patterns, and inherent bioactive substances are the ideal candidates for bacterial infection treatment. Meanwhile, advanced engineering approaches have further endowed these BEVs with more customizable properties to effectively fight against bacterial infections. Herein, the present review begins with an overview of the biogenesis and biocomponents of BEVs to better comprehend their bioactivities against bacterial infections. Their isolation and engineering approaches are then introduced, with an emphasis on the diverse genetic, physical, and chemical strategies to functionalize them with desirable capacities for the optimal treatment of bacterial infections. Recent advances in exploring the natural BEVs as antibacterial and antiadhesion agents, as well as the engineered BEVs as vaccine antigens, vaccine adjuvants, and delivery nanocarriers, are expounded successively. Discussions on the new trend of engineering BEVs as nanoweapons to combat bacterial infections, in terms of advantages and challenges, are provided at the end to expedite these BEV-based therapeutic modalities for bacterial infections from bench to bedside.

Identifiers

PMID41660640
PMCPMC12873064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.